<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18584">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02864953</url>
  </required_header>
  <id_info>
    <org_study_id>RPI 301</org_study_id>
    <nct_id>NCT02864953</nct_id>
  </id_info>
  <brief_title>CIRARA in Large Hemispheric Infarction Analyzing Modified Rankin Scale (mRS) and Mortality (CHARM)</brief_title>
  <acronym>CHARM</acronym>
  <official_title>A Randomized, Multi-center, Prospective, Double-blind, Phase 3 Trial of CIRARA (Glyburide for Injection) in Subjects With a Large Hemispheric Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Remedy Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Remedy Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the use of the investigational drug CIRARA versus placebo in patients
      with a large hemispheric infarction.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2017</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with improvement in functional outcome at 90 days assessed via the modified Rankin Scale</measure>
    <time_frame>Change from baseline at 90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with improvement in overall survival at 90 days</measure>
    <time_frame>Change from baseline at 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with a reduction in midline shift at 72 hours assessed via non-contrast computed tomography</measure>
    <time_frame>Change from baseline at 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of CIRARA via collection of adverse events and serious adverse events</measure>
    <time_frame>Change from baseline through 15 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">650</enrollment>
  <condition>Brain Edema</condition>
  <condition>Stroke, Acute</condition>
  <arm_group>
    <arm_group_label>CIRARA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CIRARA (glyburide for injection)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for CIRARA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (for CIRARA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CIRARA (glyburide for injection)</intervention_name>
    <arm_group_label>CIRARA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for CIRARA)</intervention_name>
    <arm_group_label>Placebo for CIRARA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A clinical diagnosis of acute ischemic stroke in the middle cerebral artery territory

          2. A large lesion as defined by imaging

          3. Time to the start of infusion of study drug ≤ 9 hours after time of symptom onset

          4. Age ≥ 18 and ≤ 85 years

        Exclusion Criteria:

          1. Commitment to decompressive craniectomy prior to enrollment

          2. Treatment with intra-arterial recombinant tissue plasminogen activator (rtPA) or by
             endovascular thrombectomy for clot disruption

          3. Evidence of concurrent infarction in the contralateral hemisphere sufficiently
             serious so as to affect functional outcome

          4. Clinical signs of herniation

          5. Brain hemorrhage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin N Sheth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>W. Taylor Kimberly, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Remedy Pharmaceuticals, Inc.</last_name>
  </overall_contact>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 9, 2016</lastchanged_date>
  <firstreceived_date>July 12, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Brain Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glyburide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
